General information
This study was a single‐center, randomized, controlled trial (Register number: ChiCTR2200066693). Ninety‐nine patients (58 males and 41 females; average age, 60.18 ± 9.61 years; age range, 33−77 years) with UPLA‐SS who were admitted to the Department of Intensive Care Medicine (Huai'an First Hospital, Nanjing Medical University) from March 2018 to March 2022 were enrolled in the study. The control group was treated with fluid resuscitation, supplemental oxygen, and nutritional support. The circulation was stabilized and vital organ function was maintained. During the initial stage, carbapenems (imipenem/cilastatin [1 g every 8 h] and biapenem [0.3 g every 8 h]) were administered intravenously. Treatment was then adjusted based on the results of pathogenic drug sensitivity tests, as presented in Tables Microbial species detected and antibiotics used in the two groups.Antibiotic susceptibility patterns of bacterial isolates from the two groups.Abbreviations: I, intermediate; R, resistant; S, susceptible.